FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia

21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news